View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Research Reports
September 14, 2017

Report: Sepsis and septic shock treatment to be $5.9bn market by 2026

The market for sepsis and septic shock across the seven major pharmaceutical markets of the US, France, Germany, Italy, Spain, the UK, and Japan is expected to reach $5.9bn by 2026, according to a report by GlobalData.

The market for sepsis and septic shock across the seven major pharmaceutical markets of the US, France, Germany, Italy, Spain, the UK, and Japan is expected to reach $5.9bn by 2026, according to a report by GlobalData.

Titled ‘Opportunity Analyzer: Sepsis and Septic Shock – Opportunity Analysis and Forecasts to 2026’ the report forecasts the sepsis and septic shock market to witness a compound annual growth rate (CAGR) of 7.9%, growing from $2.8bn in 2016.

Annual sales of sepsis drugs across the 7MM were approximately $2.2bn in 2016, while those of septic shock drugs were $600m.

Sepsis, a complex disease that causes organ dysfunction(s), has a high level of unmet need due to the absence of licensed products specific to the disease treatment across the 7MM.

"The US market will witness the launch of two medical devices in the future, namely Toraymyxin and CytoSorb."

Four new first-in-class pipeline drugs, namely BMS-936559, recAP, Traumakine, and CYT107, while three improved therapeutics, namely selepressin, thrombomodulin and cefiderocol are expected to be launched in the market in future, which will in turn drive the market growth.

The US market will witness the launch of two medical devices in the future, namely Toraymyxin and CytoSorb.

Sepsis treatments currently in pipeline target disseminated intravascular coagulopathy, acute lung injury, and acute kidney injury, but future opportunities will be in the development of novel therapies targeting comorbid conditions, says Christopher Pace, Director of the Infectious Disease team at GlobalData.

Involvement of multiple organs in sepsis and septic shock, however, poses a major hindrance to the development of safe, effective and tolerable treatment agents, the report adds.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology